Home > Management

  • Philip Kuo-Lung Huang
    Chairman of the Board, President, CEO and Chief Commercial Officer in Asia
    Mr. Huang joined TaiGen in 2004 as Chief Commercial Officer in Asia and General Manager of TaiGen Beijing. He dedicated to the pharmaceutical field across China and Taiwan markets around 40 years. During his tenure as the Chief Commercial Officer in 2015, Taigexyn® (Nemonoxacin) oral formulation received approval from the China Food and Drug Administration (CFDA). Also, TaiGen signed a Memorandum of Understanding with YiChang HEC Chang Jiang Pharmaceutical Co. Ltd to collaborate in research and development of a novel all-oral interferon-free treatment for chronic hepatitis C virus (HCV) infection in 2016.

    Prior to joining TaiGen, Mr. Huang was with Takeda Pharmaceutical for six years and held a number of positions including Sales and Marketing Director in Beijing, Asia Marketing Strategic Manager in Osaka, and Sales and Marketing Director in Taiwan. Before that, Mr. Huang was with Sandoz (Novartis) Taiwan and MSD Taiwan for 15 years and held various positions, most recently as the Director of Business Development and Product Management. Mr. Huang graduated from Taipei Medical College and is a licensed pharmacist.

  • Richard Lu
    Vice President, Finance
    Before enrolled as the Finance Vice President at TaiGen in April 2016, Mr. Lu has been working in the fields of corporate finance as well as accounting controlling for over 20 years. Mr. Lu is an experienced finance executive mostly in listed companies with diverse industries including petrochemical, pharmaceutical, semiconductor, 3C products manufacturing, and construction sectors. Under those positions, Mr. Lu had accomplished such strategic projects, like recapitalization, ERP implementation, corporate reorganization, that either improve the financial structure or enhance the managerial efficiency of the companies he worked for. After graduated from Rutgers, New Jersey State University, with MBA degree, Mr. Lu came back to Taiwan in 1994 and pursued his career in Asia Pacific Areas including Taiwan and China.
  • Chu-Chung Lin, Ph.D.
    Vice President, Discovery Research and Chemical Development
    Dr. Lin has over 20 years of drug discovery and chemical development in the pharmaceutical industry. Dr. Lin joined TaiGen in 2001, held the positions of Chemistry Section Head, Director and now serves as the Senior Director of Medicinal Chemistry. Prior to joining TaiGen , Dr. Lin was with National Health Research Institute and Chang-Chun Petro Chemical. Dr. Lin has extensive experience in drug discovery with emphasis on the development of novel therapeutics for infectious diseases, cancer, inflammtory , HCV and influenza. Dr Lin obtained his Ph.D. in organic chemistry from the National Chiao-Tung University in Taiwan.
  • Li-Wen Chang
    Vice President, Clinical Development
    Ms. Chang joined TaiGen in 2003, held the positions of Senior Manager, Associate Director and Senior Director of Clinical Development and now serves as the Vice President of Clinical Development Department. Ms. Chang has extensive experiences in clinical research and new drug development field, with emphasis on the therapeutic areas of infectious diseases (such as antibiotic and anti-HCV), stem cell transplantation and hematology & oncology. From 2008, Ms. Chang led the medical science team to work on the clinical trials of Nemonoxacin, Burixafor and Furaprevir in the United States, Mainland China and Taiwan. Ms. Chang obtained her master degree in Biochemistry and Molecular Biology from National Cheng-Kung University in Taiwan.
  • Cheng-Yuan Tsai, Ph.D.
    Senior Director, Preclinical Development
    Dr. Tsai joined TaiGen Biotechnology in April 2006, held the positions of Senior Director, Director of DMPK of Preclinical Department and now serves as the Senior Director of Preclinical Research Department. Prior to joining TaiGen, Dr. Tsai was Head of ADME of Department of Toxicology and Preclinical Sciences at Development Center for Biotechnology (DCB). During the DCB period, Dr. Tsai was also as the part-time Patent Reviewer of Intellectual Property Office, Taiwan and the part-time Assistant Professor of the Department of Chemistry of Soochow University. Dr. Tsai has over 20 years of DMPK in preclinical drug development and received his Ph.D. in Analytical Chemistry from the National Taiwan University in Taiwan.